Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

Phase 3

Completed

Conditions: Malaria
HIV Infections

Interventions: Drug: Lopinavir/ritonavir
Drug: Efavirenz
Drug: Zidovudine
Drug: Lamivudine

First Posted Date: 2009-10-09

Last Posted Date: 2019-05-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 389

Registration Number: NCT00993031

Locations: 🇺🇬
Tororo District Hospital, Tororo, Uganda

Efavirenz in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: efavirenz

First Posted Date: 2009-08-24

Last Posted Date: 2022-05-16

Lead Sponsor: Institut Bergonié

Target Recruit Count: 61

Registration Number: NCT00964002

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Conditions: Pancreatic Cancer

First Posted Date: 2009-08-24

Last Posted Date: 2010-04-07

Lead Sponsor: Institut Bergonié

Target Recruit Count: 72

Registration Number: NCT00964171

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1349572
Drug: efavirenz

First Posted Date: 2009-08-03

Last Posted Date: 2018-01-16

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 208

Registration Number: NCT00951015

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Phase 2

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: Stribild
Drug: Atripla

First Posted Date: 2009-03-26

Last Posted Date: 2014-06-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 71

Registration Number: NCT00869557

Locations: 🇺🇸
Northstar Medical Center, Chicago, Illinois, United States
🇺🇸
Southampton Healthcare, Inc., St. Louis, Missouri, United States
🇺🇸
Gordon E. Crofoot, MD, PA, Houston, Texas, United States

and more 27 locations

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Phase 2

Completed

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: efavirenz
Drug: raltegravir

First Posted Date: 2009-01-14

Last Posted Date: 2013-07-17

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 155

Registration Number: NCT00822315

Locations: 🇧🇷
Ipec/Fiocruz, Rio de Janeiro, Brazil
🇧🇷
Hospitral Universitario Pr Edgar Santos, Salvador da Bahia, Brazil
🇫🇷
Hôpital Saint-Louis, Paris, France

and more 6 locations

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz

Not Applicable

Completed

Conditions: Sleep Disorders

Interventions: Drug: efavirenz
Drug: etravirine

First Posted Date: 2008-11-18

Last Posted Date: 2011-09-12

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 50

Registration Number: NCT00792584

Locations: 🇨🇭
Geneva Hospital, Geneva, Switzerland

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

Phase 3

Completed

Conditions: HIV

Interventions: Drug: Etravirine
Drug: Efavirenz

First Posted Date: 2008-11-17

Last Posted Date: 2009-11-18

Lead Sponsor: St Stephens Aids Trust

Target Recruit Count: 24

Registration Number: NCT00792324

Locations: 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Phase 4

Terminated

Conditions: Acquired Immune Deficiency Syndrome

Interventions: Drug: Lopinavir 400 mg/ritonavir 100 mg
Drug: Efavirenz

First Posted Date: 2008-10-20

Last Posted Date: 2023-05-26

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 15

Registration Number: NCT00775606

Locations: 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Hospital, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Kaletra + Isentress
Drug: Atripla

First Posted Date: 2008-09-16

Last Posted Date: 2020-07-22

Lead Sponsor: University of California, San Diego

Target Recruit Count: 51

Registration Number: NCT00752856

Locations: 🇺🇸
Living Hope Clinical Foundation, Long Beach, California, United States
🇺🇸
Desert AIDS Project, Palm Springs, California, United States
🇺🇸
Univerisity California Irvine, Orange, California, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy